Investors News September 28, 2026Link Cell Therapies Initiates Clinical Dosing with Logic-Gated CAR-T Therapy, Expands Executive Leadership, and Upsizes Series A Financing to $90 MillionRead MoreJanuary 9, 2026Link Cell Therapies Enters into Strategic Collaboration with Johnson & Johnson to Develop Logic-Gate LINK CAR T TherapiesRead More
